Browse
Prediction results retrieved after performance evaluation of WHO approved 34 primers to estimate their binding affinities for 3892 SARS-CoV-2 variants.

Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used
  
AA.8NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
AA.8NNIID-JP-NTGGCAGCTGTGTAGGTCAAC20552928229263R-20522.3Japan
B.1.1.133NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
B.1.1.133NNIID-JP-NTGGCAGCTGTGTAGGTCAAC20552928229263R-20522.3Japan
B.18NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
B.18NNIID-JP-NTGGCAGCTGTGTAGGTCAAC20552928229263R-20522.3Japan
B.1.1.466NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
B.1.1.466NNIID-JP-NTGGCAGCTGTGTAGGTCAAC20552928229263R-20522.3Japan
B.1.489NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
B.1.489NNIID-JP-NTGGCAGCTGTGTAGGTCAAC20552928229263R-20522.3Japan
B.1.1.363NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
B.1.1.363NNIID-JP-NTGGCAGCTGTGTAGGTCAAC20552928229263R-20522.3Japan
B.1.67NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
B.1.67NNIID-JP-NTGGCAGCTGTGTAGGTCAAC20552928229263R-20522.3Japan
B.1.1.190NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
B.1.1.190NNIID-JP-NTGGCAGCTGTGTAGGTCAAC20552928229263R-20522.3Japan
B.1.120NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
B.1.120NNIID-JP-NTGGCAGCTGTGTAGGTCAAC20552928229263R-20522.3Japan
AM.3NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
AM.3NNIID-JP-NTGGCAGCTGTGTAGGTCAAC20552928229263R-20522.3Japan
AA.2NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
AA.2NNIID-JP-NTGGCAGCTGTGTAGGTCAAC20552928229263R-20522.3Japan
B.1.1.249NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
B.1.1.249NNIID-JP-NTGGCAGCTGTGTAGGTCAAC20552928229263R-20522.3Japan
N.8NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-2840.1Japan
N.8NNIID-JP-NTGGCAGCTGTGTAGGTCAAC20552928229263R-2113.71Japan
XANNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
XANNIID-JP-NTGGCAGCTGTGTAGGTCAAC20552928229263R-20522.3Japan
AZ.4NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
AZ.4NNIID-JP-NTGGCAGCTGTGTAGGTCAAC20552928229263R-20522.3Japan
B.1.1.114NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
B.1.1.114NNIID-JP-NTGGCAGCTGTGTAGGTCAAC20552928229263R-20522.3Japan
B.1.177.39NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
B.1.177.39NNIID-JP-NTGGCAGCTGTGTAGGTCAAC20552928229263R-20522.3Japan
B.1.199NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
B.1.199NNIID-JP-NTGGCAGCTGTGTAGGTCAAC20552928229263R-20522.3Japan
AY.112.1 (Delta)NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
AY.112.1 (Delta)NNIID-JP-NTGGCAGCTGTGTAGGTCAAC20552928229263R-20522.3Japan
B.1.1.360NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
B.1.1.360NNIID-JP-NTGGCAGCTGTGTAGGTCAAC20552928229263R-20522.3Japan
B.1.177.49NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
B.1.177.49NNIID-JP-NTGGCAGCTGTGTAGGTCAAC20552928229263R-20522.3Japan
B.1.1.347NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
B.1.1.347NNIID-JP-NTGGCAGCTGTGTAGGTCAAC20552928229263R-20522.3Japan
B.1.195NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
B.1.195NNIID-JP-NTGGCAGCTGTGTAGGTCAAC20552928229263R-20522.3Japan
B.1.321NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
B.1.321NNIID-JP-NTGGCAGCTGTGTAGGTCAAC20552928229263R-20522.3Japan
B.1.1.379NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
B.1.1.379NNIID-JP-NTGGCAGCTGTGTAGGTCAAC20552928229263R-20522.3Japan
Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used